ClinicalTrials.gg
CompletedNCT00907478Updated Sep 21, 2022Results posted

Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)

A Phase 4 interventional study of romiplostim in Thrombocytopenia and Idiopathic Thrombocytopenic Purpura, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-21.

Primary conditionPurpura, Thrombocytopenic, IdiopathicRegistry: ThrombocytopeniaReclassifiedWhy we changed it
Registry
Thrombocytopenia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Purpura, Thrombocytopenic, Idiopathic
Why
  1. The study's listed conditions name Purpura, Thrombocytopenic, Idiopathic, a narrower term within Thrombocytopenia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
169
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
7th of 29
169 · median 62
Started
2009
with 2 others
Phase 4
3 of 29
1 open now
Registered
11th of 29
by date
Lead sponsor
14 of 29
Amgen

Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 7th largest by enrollment, is one of 3 that started in 2009, is one of 3 in phase 4, and was the 11th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate changes in bone marrow morphology (structure) after long-term exposure to romiplostim.

Read the detailed description

Participants diagnosed with ITP according to the American Society of Hematology (ASH) Guidelines were sequentially enrolled into the following groups:

  • Bone marrow biopsy at Baseline and Year 1
  • Bone marrow biopsy at Baseline and Year 2
  • Bone marrow biopsy at Baseline and Year 3.

All participants received romiplostim for 3 years, unless withdrawn from the study early. Participants returned for one visit for End of Study (EOS) procedures 4 weeks after romiplostim discontinuation, or, for participants who were withdrawn from the study due to the presence of collagen fibrosis, or had a change to grade 3 reticulin, at 12 weeks after discontinuation of romiplostim.

03

Conditions studied

  • Thrombocytopenia
  • Idiopathic Thrombocytopenic Purpura

Browse trials for

Keywords

  • Idiopathic Thrombocytopenic Purpura
  • Idiopathic Thrombocytopenia Purpura
  • Immune Thrombocytopenic Purpura
  • Immune Thrombocytopenia
  • ITP
04

In context

Purpura, Thrombocytopenic, Idiopathic Reclassified

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

This study's enrollment of 169 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Purpura, Thrombocytopenic, Idiopathic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Thrombocytopenia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ITP according to American Society of Hematology (ASH) guidelines
  • Subject must have had a bone marrow within one year prior to planned first dose of romiplostim (with available bone marrow tissue block or unstained histological slides to send to a central laboratory for interpretation) or must consent to a pre-treatment bone marrow biopsy within 3 weeks prior to planned first dose of romiplostim. Central laboratory interpretation is required prior to first dose of romiplostim
  • Subject must agree to a scheduled bone marrow biopsy at Year 1, Year 2, or Year 3 following romiplostim treatment and any unscheduled biopsies if clinically indicated
  • Subject ≥18 years of age
  • Baseline bone marrow reticulin grade of 0, 1, 2, or 3 according to the modified Bauermeister grading scheme as assessed by central laboratory interpretation
  • count \< 50 x 10\^9/L
  • Must have received at least 1 prior ITP therapy (examples of ITP therapy include , intravenous immunoglobulin [IVIG], splenectomy)
  • Subject (or legally-acceptable representative) is willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Baseline bone marrow positive for collagen fibrosis
  • Any known history of or currently active bone marrow stem cell disorder, hematological , myeloproliferative disorder, myelodysplastic syndrome
  • Any current active malignancy
  • Any prior exposure to cytostatic chemotherapy or radiotherapy for malignancy
  • Subject has undergone pacemaker placement, cardiac ablation of arrhythmia, and/or any current treatment with Vaughan Williams Class IA - IC and Class III agents (Vaughan Williams, 1970)
  • Subject has participated in any study evaluating pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO), or thrombopoietin receptor agonists (ie romiplostim or eltrombopag)
  • Subject has a known to any recombinant E coli-derived product
  • Subject is currently enrolled in or has not yet completed (at least 4 weeks since ending) other device or drug trial(s) or subject is receiving other investigational agent(s)
  • Other investigational procedures are excluded
  • Subject of is evidently pregnant (eg positive pregnancy test) or is breast feeding
  • Subject is not using adequate precautions
  • Subject has any kind of disorder that compromises the ability of the subject to give written and does not have a legally acceptable representative and/or is unable to comply with study procedures.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
169 participants (actual)

Study arms

  • Experimental
    Romiplostim

    Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose of romiplostim was 1 μg/kg; weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L.

    Biological: romiplostim

Interventions

  • Biologicalromiplostim

    Romiplostim administered by subcutaneous injection

    Also known as: Nplate®

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Collagen Fibrosis

    The percentage of participants who developed collagen fibrosis as evidenced by trichrome staining. Bone marrow biopsy samples were assessed using the modified Bauermeister grading scale by a central laboratory.

    Time frame: At Years 1, 2 or 3 after initial exposure of romiplostim

Secondary outcomes

  1. Number of Participants With Collagen Fibrosis 12 Weeks After Romiplostim Discontinuation in Participants Who Developed Collagen Fibrosis at Years 1, 2, or 3

    The number of participants with collagen fibrosis as evidenced by trichrome staining 12 weeks after romiplostim discontinuation in participants who developed collagen fibrosis at Years 1, 2, or 3 after initial exposure of romiplostim, assessed by the central laboratory using the modified Bauermeister grading scale.

    Time frame: 12 weeks after romiplostim discontinuation

  2. Percentage of Participants Who Developed an Increased Modified Bauermeister Grade

    Increased modified Bauermeister grade refers to an increase by ≥ 2 severity grades or an increase to grade 4 (ie, grade 0 to 2-4, grade 1 to 3-4, grade 2 to 4, or grade 3 to 4 over baseline). The modified Bauermeister scale provides a means of assessing the development of increased reticulin and collagen in bone marrow according to the following: Grade 0: No reticulin fibers demonstrable; Grade 1: Occasional fine individual fibers and foci of a fine fiber network; Grade 2: Fine fiber network throughout most of the section; no coarse fibers; Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining); Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining).

    Time frame: At Year 1, Year 2, or Year 3 post romiplostim exposure

  3. Percentage of Participants With Clinically Relevant Changes in Total Cardiac Output Corrected (QTc) Intervals

    A clinically relevant change in QTc (Fridericia) interval is defined as an absolute QTc interval \>500 ms or a QTc Interval increase from Baseline \>60 ms post romiplostim exposure. 12-lead electrocardiograms (ECG) were performed in triplicate at Baseline, Week 3 and Week 12; the average of of the 3 values at each assessment was used.

    Time frame: Baseline, Week 3 and Week 12

  4. Number of Participants With Improvement of Reticulin to a Grade of ≤ 2 for Participants Who Developed Grade 3 Reticulin

    The number of participants who had any improvement of reticulin to a grade of ≤ 2 for participants who developed grade 3 reticulin after initial exposure to romiplostim as measured by the modified Bauermeister grading scale. The modified Bauermeister scale provides a means of assessing the development of increased reticulin and collagen in bone marrow according to the following: Grade 0: No reticulin fibers demonstrable; Grade 1: Occasional fine individual fibers and foci of a fine fiber network; Grade 2: Fine fiber network throughout most of the section; no coarse fibers; Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining); Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining).

    Time frame: 12 weeks after romiplostim discontinuation

  5. Percentage of Participants With CTCAE Grade ≥ 2 Shift in Anemia or Neutropenia

    Anemia was identified by laboratory values with hemoglobin \< the lower limit of normal (LLN) or the Medical Dictionary for Regulatory Activities (MedDRA) terms prespecified by the sponsor. Neutropenia was identified by laboratory values with absolute neutrophil count \<1.8x10\^9/L or the MedDRA terms pre-specified by the sponsor. Severity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, based on the following: Grade 1: Mild AE; Grade 2: Moderate AE; Grade 3: Severe AE; Grade 4: Life-threatening or disabling AE; Grade 5: Death related to AE.

    Time frame: From the first dose of study drug until 4 weeks after treatment discontinuation or 12 weeks after treatment discontinuation for patients who developed collagen fibrosis or a change to grade 3 reticulin; the overall median treatment duration was 154 weeks.

  6. Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant that did not necessarily have a causal relationship with this treatment, or any such occurrence or worsening of a pre-existing medical condition from the first dose of investigational product through the last study visit. A serious adverse event is defined as an AE that is fatal or life threatening, requires or prolongs hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or other significant medical hazard. The relationship of each AE to the study drug was assessed by the investigator. The severity of each AE was graded using using CTCAE 3.0; For any AEs not listed in CTCAE, the Amgen Standard Severity Scoring System was used: 1: Mild- Aware of sign or symptom, but easily tolerated; 2 Moderate- Discomfort enough to cause interference with usual activity; 3: Severe- Incapacitating with inability to work or do usual activity; 4: Life-threatening; 5: Fatal.

    Time frame: From the first dose of study drug until 4 weeks after treatment discontinuation or 12 weeks after treatment discontinuation for patients who developed collagen fibrosis or a change to grade 3 reticulin; the overall median treatment duration was 154 weeks.

  7. Number of Participants Who Developed Antibodies or Neutralizing Antibodies to Romiplostim or to Endogenous Thrombopoietin

    Two validated assays were used to test for antibodies to romiplostim, the thrombopoietin-mimetic peptide component of romiplostim (TMP) and to endogenous thrombopoietin (TPO). The first was an immunoassay to confirm the presence of antibodies. The second was a cell-based bioassay to detect neutralizing or inhibitory effects in vitro. If a sample was positive in both assays, a participant was defined as positive for neutralizing antibodies. Persistent antibodies were those positive at the last timepoint tested and transient are defined as positive post-dose but negative at the last time point tested.

    Time frame: Every 24 weeks and at the end of study visit (4 weeks or 12 weeks after study drug discontinuation).

08

Results

Posted Jan 1, 2015

Participant flow

Eligible patients were adults diagnosed with immune (idiopathic) thrombocytopenic purpura (ITP) with a platelet count \< 50 x 10\^9/L. The first patient enrolled 11 August 2009 and the last patient was enrolled 11 November 2010. Participants were enrolled at 60 study centers in Australia, Europe, and North America.

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3
Started505069
Completed233347
Not completed271722
Withdrew: Ineligibility determined001
Withdrew: Noncompliance001
Withdrew: Adverse event312
Withdrew: Withdrawal by subject896
Withdrew: Requirement for alternative therapy123
Withdrew: Physician decision203
Withdrew: Death421
Withdrew: Protocol-specified criteria523
Withdrew: Pregnancy011
Withdrew: Lost to follow-up100
Withdrew: Other301

Outcome measures

PrimaryPercentage of Participants With Collagen Fibrosis

The percentage of participants who developed collagen fibrosis as evidenced by trichrome staining. Bone marrow biopsy samples were assessed using the modified Bauermeister grading scale by a central laboratory.

Time frame:
At Years 1, 2 or 3 after initial exposure of romiplostim
Reported as:
Number · percentage of participants
Percentage of Participants With Collagen Fibrosis
percentage of participantsCohort 1Cohort 2Cohort 3
Percentage of Participants With Collagen Fibrosis0.0 (0.0 to 10.0)0.0 (0.0 to 9.0)3.4 (0.4 to 11.9)
SecondaryNumber of Participants With Collagen Fibrosis 12 Weeks After Romiplostim Discontinuation in Participants Who Developed Collagen Fibrosis at Years 1, 2, or 3

The number of participants with collagen fibrosis as evidenced by trichrome staining 12 weeks after romiplostim discontinuation in participants who developed collagen fibrosis at Years 1, 2, or 3 after initial exposure of romiplostim, assessed by the central laboratory using the modified Bauermeister grading scale.

Time frame:
12 weeks after romiplostim discontinuation
Reported as:
Number · participants
Number of Participants With Collagen Fibrosis 12 Weeks After Romiplostim Discontinuation in Participants Who Developed Collagen Fibrosis at Years 1, 2, or 3
participantsCohort 1Cohort 2Cohort 3
Number of Participants With Collagen Fibrosis 12 Weeks After Romiplostim Discontinuation in Participants Who Developed Collagen Fibrosis at Years 1, 2, or 3——0
SecondaryPercentage of Participants Who Developed an Increased Modified Bauermeister Grade

Increased modified Bauermeister grade refers to an increase by ≥ 2 severity grades or an increase to grade 4 (ie, grade 0 to 2-4, grade 1 to 3-4, grade 2 to 4, or grade 3 to 4 over baseline). The modified Bauermeister scale provides a means of assessing the development of increased reticulin and collagen in bone marrow according to the following: Grade 0: No reticulin fibers demonstrable; Grade 1: Occasional fine individual fibers and foci of a fine fiber network; Grade 2: Fine fiber network throughout most of the section; no coarse fibers; Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining); Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining).

Time frame:
At Year 1, Year 2, or Year 3 post romiplostim exposure
Reported as:
Number · percentage of participants
Percentage of Participants Who Developed an Increased Modified Bauermeister Grade
percentage of participantsCohort 1Cohort 2Cohort 3
Percentage of Participants Who Developed an Increased Modified Bauermeister Grade0.0 (0.0 to 10.3)5.1 (0.6 to 17.3)12.1 (5.0 to 23.3)
SecondaryPercentage of Participants With Clinically Relevant Changes in Total Cardiac Output Corrected (QTc) Intervals

A clinically relevant change in QTc (Fridericia) interval is defined as an absolute QTc interval \>500 ms or a QTc Interval increase from Baseline \>60 ms post romiplostim exposure. 12-lead electrocardiograms (ECG) were performed in triplicate at Baseline, Week 3 and Week 12; the average of of the 3 values at each assessment was used.

Time frame:
Baseline, Week 3 and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Relevant Changes in Total Cardiac Output Corrected (QTc) Intervals
percentage of participantsCohort 1Cohort 2Cohort 3
Percentage of Participants With Clinically Relevant Changes in Total Cardiac Output Corrected (QTc) Intervals0.0 (0.0 to 7.1)0.0 (0.0 to 7.1)0.0 (0.0 to 5.2)
SecondaryNumber of Participants With Improvement of Reticulin to a Grade of ≤ 2 for Participants Who Developed Grade 3 Reticulin

The number of participants who had any improvement of reticulin to a grade of ≤ 2 for participants who developed grade 3 reticulin after initial exposure to romiplostim as measured by the modified Bauermeister grading scale. The modified Bauermeister scale provides a means of assessing the development of increased reticulin and collagen in bone marrow according to the following: Grade 0: No reticulin fibers demonstrable; Grade 1: Occasional fine individual fibers and foci of a fine fiber network; Grade 2: Fine fiber network throughout most of the section; no coarse fibers; Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining); Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining).

Time frame:
12 weeks after romiplostim discontinuation
Reported as:
Number · participants
Number of Participants With Improvement of Reticulin to a Grade of ≤ 2 for Participants Who Developed Grade 3 Reticulin
participantsCohort 1Cohort 2Cohort 3
Number of Participants With Improvement of Reticulin to a Grade of ≤ 2 for Participants Who Developed Grade 3 Reticulin——3
SecondaryPercentage of Participants With CTCAE Grade ≥ 2 Shift in Anemia or Neutropenia

Anemia was identified by laboratory values with hemoglobin \< the lower limit of normal (LLN) or the Medical Dictionary for Regulatory Activities (MedDRA) terms prespecified by the sponsor. Neutropenia was identified by laboratory values with absolute neutrophil count \<1.8x10\^9/L or the MedDRA terms pre-specified by the sponsor. Severity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, based on the following: Grade 1: Mild AE; Grade 2: Moderate AE; Grade 3: Severe AE; Grade 4: Life-threatening or disabling AE; Grade 5: Death related to AE.

Time frame:
From the first dose of study drug until 4 weeks after treatment discontinuation or 12 weeks after treatment discontinuation for patients who developed collagen fibrosis or a change to grade 3 reticulin; the overall median treatment duration was 154 weeks.
Reported as:
Number · percentage of participants
Percentage of Participants With CTCAE Grade ≥ 2 Shift in Anemia or Neutropenia
percentage of participantsCohort 1Cohort 2Cohort 3
CTCAE grade ≥2 shift in anemia6.0 (1.3 to 16.5)4.0 (0.5 to 13.7)8.7 (3.3 to 18.0)
CTCAE grade ≥2 shift in neutropenia8.0 (2.2 to 19.2)6.0 (1.3 to 16.5)13.0 (6.1 to 23.3)
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant that did not necessarily have a causal relationship with this treatment, or any such occurrence or worsening of a pre-existing medical condition from the first dose of investigational product through the last study visit. A serious adverse event is defined as an AE that is fatal or life threatening, requires or prolongs hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or other significant medical hazard. The relationship of each AE to the study drug was assessed by the investigator. The severity of each AE was graded using using CTCAE 3.0; For any AEs not listed in CTCAE, the Amgen Standard Severity Scoring System was used: 1: Mild- Aware of sign or symptom, but easily tolerated; 2 Moderate- Discomfort enough to cause interference with usual activity; 3: Severe- Incapacitating with inability to work or do usual activity; 4: Life-threatening; 5: Fatal.

Time frame:
From the first dose of study drug until 4 weeks after treatment discontinuation or 12 weeks after treatment discontinuation for patients who developed collagen fibrosis or a change to grade 3 reticulin; the overall median treatment duration was 154 weeks.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsCohort 1Cohort 2Cohort 3
All adverse events464567
Grade ≥ 2393959
Grade ≥ 3252138
Grade ≥ 413816
Serious adverse events161228
Leading to discontinuation of study drug654
Leading to discontinuation from study623
Fatal adverse events421
Treatment-related adverse events142224
Treatment-related grade ≥ 281410
Treatment-related grade ≥ 3273
Treatment-related grade ≥ 4010
Treatment-related serious adverse events123
Treatment-related -> discontinuation of study drug112
Treatment-related -> discontinuation from study102
Treatment-related fatal adverse events000
SecondaryNumber of Participants Who Developed Antibodies or Neutralizing Antibodies to Romiplostim or to Endogenous Thrombopoietin

Two validated assays were used to test for antibodies to romiplostim, the thrombopoietin-mimetic peptide component of romiplostim (TMP) and to endogenous thrombopoietin (TPO). The first was an immunoassay to confirm the presence of antibodies. The second was a cell-based bioassay to detect neutralizing or inhibitory effects in vitro. If a sample was positive in both assays, a participant was defined as positive for neutralizing antibodies. Persistent antibodies were those positive at the last timepoint tested and transient are defined as positive post-dose but negative at the last time point tested.

Time frame:
Every 24 weeks and at the end of study visit (4 weeks or 12 weeks after study drug discontinuation).
Reported as:
Number · participants
Number of Participants Who Developed Antibodies or Neutralizing Antibodies to Romiplostim or to Endogenous Thrombopoietin
participantsRomiplostim
Antibodies to romiplostim7
Persistent antibodies to romiplostim4
Transient antibodies to romiplostim3
Antibodies to TMP4
Persistent antibodies to TMP1
Transient antibodies to TMP3
Antibodies to TPO6
Persistent antibodies to TPO2
Transient antibodies to TPO4
Neutralizing antibodies to romiplostim1
Neutralizing antibodies to TPO0

Adverse events

Collected over From the first dose of study drug until 4 weeks after treatment discontinuation or 12 weeks after treatment discontinuation for patients who developed collagen fibrosis or a change to grade 3 reticulin; the overall median treatment duration was 154 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1—16/50 (32%)45/50 (90%)
Cohort 2—12/50 (24%)43/50 (86%)
Cohort 3—28/69 (40.6%)66/69 (95.7%)
Overall—56/169 (33.1%)154/169 (91.1%)
Most frequent serious events
Showing 10 of 99
Most frequent serious events
EventCohort 1Cohort 2Cohort 3Overall
ThrombocytopeniaBlood and lymphatic system disorders2/500/504/696/169
Urinary Tract InfectionInfections and infestations2/501/500/693/169
Cerebrovascular AccidentNervous system disorders2/500/500/692/169
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/502/500/692/169
AnaemiaBlood and lymphatic system disorders1/500/502/693/169
Idiopathic Thrombocytopenic PurpuraBlood and lymphatic system disorders0/501/502/693/169
Atrial FibrillationCardiac disorders0/500/502/692/169
CholecystitisHepatobiliary disorders0/500/502/692/169
PneumoniaInfections and infestations0/500/502/692/169
OsteoarthritisMusculoskeletal and connective tissue disorders0/500/502/692/169
Most frequent other events
Showing 10 of 64
Most frequent other events
EventCohort 1Cohort 2Cohort 3Overall
NasopharyngitisInfections and infestations6/5021/5014/6941/169
HeadacheNervous system disorders12/5014/5025/6951/169
ContusionInjury, poisoning and procedural complications6/509/5019/6934/169
ArthralgiaMusculoskeletal and connective tissue disorders8/5010/5019/6937/169
DiarrhoeaGastrointestinal disorders7/507/5018/6932/169
EpistaxisRespiratory, thoracic and mediastinal disorders9/5010/5018/6937/169
Upper Respiratory Tract InfectionInfections and infestations11/507/5013/6931/169
PetechiaeSkin and subcutaneous tissue disorders9/5011/5014/6934/169
Gingival BleedingGastrointestinal disorders3/505/5013/6921/169
CoughRespiratory, thoracic and mediastinal disorders4/507/5013/6924/169

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Total
Mean55.5 ± 17.148.6 ± 16.546.6 ± 16.349.8 ± 16.9
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Total
Female273849114
Male23122055
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Cohort 1Cohort 2Cohort 3Total
White or Caucasian484759154
Black or African American0011
Hispanic or Latino13711
Asian1012
Other0011
Time Since ITP Diagnosis
Time Since ITP Diagnosis(years)Cohort 1Cohort 2Cohort 3Total
Mean9.94 ± 10.2910.50 ± 11.875.36 ± 6.418.24 ± 9.72
Number of Prior ITP Therapies
Number of Prior ITP Therapies(participants)Cohort 1Cohort 2Cohort 3Total
00000
116162961
211152046
3891027
≥ 415101035
Had Splenectomy
Had Splenectomy(participants)Cohort 1Cohort 2Cohort 3Total
No283546109
Yes22152360
Any Prior History of Bone Marrow Abnormalities
Any Prior History of Bone Marrow Abnormalities(participants)Cohort 1Cohort 2Cohort 3Total
No484764159
Yes23510
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • Janssens A, Rodeghiero F, Anderson D, Chong BH, Boda Z, Pabinger I, Cervinek L, Terrell DR, Wang X, Franklin J. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. Ann Hematol. 2016 Jun;95(7):1077-87. doi: 10.1007/s00277-016-2682-2. Epub 2016 Apr 30. PubMed 27130310 ↗
  • Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D, Lyons R, Garcia-Chavez J, Carpenter N, Wang X, Eisen M. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017 Aug;102(8):1342-1351. doi: 10.3324/haematol.2016.161968. Epub 2017 Apr 14. PubMed 28411254 ↗
  • Kuter DJ, Newland A, Chong BH, Rodeghiero F, Romero MT, Pabinger I, Chen Y, Wang K, Mehta B, Eisen M. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol. 2019 May;185(3):503-513. doi: 10.1111/bjh.15803. Epub 2019 Feb 21. PubMed 30793285 ↗
  • Kuter DJ, Arnold DM, Rodeghiero F, Janssens A, Selleslag D, Bird R, Newland A, Mayer J, Wang K, Olie R. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. Am J Hematol. 2020 Jun;95(6):643-651. doi: 10.1002/ajh.25776. Epub 2020 Mar 21. PubMed 32129511 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2009 to primary completion in Jan 2014, 52 months.

Results were first posted in Jan 2015, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2009
First posted
May 22, 2009
StartActual
Aug 11, 2009
Primary completionActual
Jan 9, 2014
CompletionActual
Jan 14, 2014
Results first posted
Jan 1, 2015
Last update
Sep 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00907478
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 22, 2009
Start date
Aug 11, 2009
Primary completion
Jan 9, 2014
Completion
Jan 14, 2014
Results posted
Jan 1, 2015
Last update
Sep 21, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion